BICO Group AB
OTC:CLLKF
BICO Group AB
BICO Group AB is a bioconvergence company, which engages in the provision of technologies, products, and services to create, understand and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 890 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
BICO Group AB is a bioconvergence company, which engages in the provision of technologies, products, and services to create, understand and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 890 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Organic Growth: BICO delivered 12% organic sales growth in Q3, with Life Science Solutions up 4% and Lab Automation rebounding strongly with 35% organic growth after a weak Q2.
Strong Lab Automation Demand: Secured significant new orders in Lab Automation, including a USD 15.2 million contract with a global pharma company, reflecting sustained industry demand.
Margins & Cost Control: Adjusted EBITDA margin improved to 5%, up 3 percentage points year-over-year, driven by cost control, process improvements, and operational synergies.
Cash Position Strengthened: Divestments of MatTek and Visikol generated SEK 740 million, boosting the cash position to SEK 1,241 million and leaving the company with a positive net cash position.
Impairments: SEK 1,036 million in non-cash impairments for Discover ECHO and Biosero impacted EBIT but do not affect cash flow.
Operational Efficiency: Management emphasized ongoing operational improvements, new leadership at Biosero, and scalable cost base to support future growth and margin expansion.
Product Innovation: Continued investments in R&D and recent product launches, with a robust innovation pipeline and multiple launches planned for 2026.
Guidance: Management reiterated a long-term annual growth target of around 10% CAGR for Discover ECHO and Biosero.
